Ascletis Pharma Inc (2VJ) — Cash Flow-to-Debt Ratio
Latest as of June 2023:
-0.37x
Ascletis Pharma Inc (2VJ) has a Cash Flow-to-Debt Ratio of -0.37x as of June 2023, meaning its operating cash flow of €-33.98 Million could theoretically repay 0% of its total liabilities (€90.79 Million) in one year. See Ascletis Pharma Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.37x
Operating CF / Total Liabilities
Operating Cash Flow
€-33.98 Million
EUR
Total Liabilities
€90.79 Million
EUR
Data as of
Jun 2023
Most recent filing
Ascletis Pharma Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Ascletis Pharma Inc across 10 annual periods. For the full cash flow conversion analysis, see how efficiently does Ascletis Pharma Inc generate cash.
Annual Cash Flow-to-Debt Ratio for Ascletis Pharma Inc (2016–2025)
Year-by-year debt coverage analysis for Ascletis Pharma Inc.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.15x | €-416.78 Million | €132.26 Million | ▼ -46.1% |
| 2024 | -2.16x | €-341.58 Million | €158.41 Million | ▼ -43.5% |
| 2023 | -1.50x | €-223.79 Million | €148.94 Million | ▼ -23.6% |
| 2022 | -1.22x | €-142.45 Million | €117.16 Million | ▲ +16.5% |
| 2021 | -1.46x | €-146.93 Million | €100.89 Million | ▼ -46.5% |
| 2020 | -0.99x | €-84.91 Million | €85.42 Million | ▼ -36.6% |
| 2019 | -0.73x | €-74.34 Million | €102.17 Million | ▲ +24.5% |
| 2018 | -0.96x | €-96.59 Million | €100.19 Million | ▲ +40.9% |
| 2017 | -1.63x | €-198.06 Million | €121.42 Million | ▼ -1559.8% |
| 2016 | -0.10x | €-12.50 Million | €127.18 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.